Review: taking Pantoprazole sodium and Mesalamine together


Summary

Drug interactions are reported among people who take Pantoprazole sodium and Mesalamine together. This review analyzes the effectiveness and drug interactions between Pantoprazole sodium and Mesalamine. It is created by eHealthMe based on reports of 895 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Pantoprazole sodium and Mesalamine >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Pantoprazole Sodium

Pantoprazole sodium has active ingredients of pantoprazole sodium. It is often used in gastrooesophageal reflux disease. (latest outcomes from Pantoprazole sodium 12,646 users)

Mesalamine

Mesalamine has active ingredients of mesalamine. It is often used in crohn's disease. (latest outcomes from Mesalamine 4,981 users)

On Jul, 23, 2016

895 people who take Pantoprazole Sodium, Mesalamine are studied.


Number of reports submitted per year:

Pantoprazole sodium and Mesalamine drug interactions.

Drug effectiveness over time:

Pantoprazole Sodium:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 50.0% - (1 of 2 people)
  • 6 - 12 months: 66.0% - (2 of 3 people)
  • 1 - 2 years: 75.0% - (3 of 4 people)
  • 2 - 5 years: 40.0% - (2 of 5 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 1 people)
  • not specified: 0.0% - (0 of 1 people)
Mesalamine:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 33.0% - (1 of 3 people)
  • 6 - 12 months: 66.0% - (2 of 3 people)
  • 1 - 2 years: 50.0% - (1 of 2 people)
  • 2 - 5 years: 25.0% - (1 of 4 people)
  • 5 - 10 years: 50.0% - (1 of 2 people)
  • 10+ years: 66.0% - (2 of 3 people)
  • not specified: 100.0% - (1 of 1 people)

Drug effectiveness by gender:

Pantoprazole Sodium:
  • female: 53.0% - (7 of 13 people)
  • male: 40.0% - (2 of 5 people)
Mesalamine:
  • female: 41.0% - (5 of 12 people)
  • male: 66.0% - (4 of 6 people)

Drug effectiveness by age:

Pantoprazole Sodium:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 50.0% - (1 of 2 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 80.0% - (4 of 5 people)
  • 50-59: 40.0% - (2 of 5 people)
  • 60+: 50.0% - (2 of 4 people)
Mesalamine:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 50.0% - (1 of 2 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 80.0% - (4 of 5 people)
  • 50-59: 60.0% - (3 of 5 people)
  • 60+: 25.0% - (1 of 4 people)

Most common drug interactions over time *:

< 1 month:
  • colitis ulcerative
  • colostomy
  • hospitalisation
  • cerebral haemorrhage
  • colitis
  • diarrhoea
  • neoplasm malignant
  • pancytopenia
  • respiratory failure
  • vascular occlusion
1 - 6 months:
  • weight decreased
  • bone pain
  • diarrhoea
  • rash
  • abdominal pain upper
  • acne
  • back pain
  • blood cortisol decreased
  • body height decreased
  • calcium metabolism disorder
6 - 12 months:
  • vulval abscess
  • pneumonitis
  • abdominal pain
  • deep vein thrombosis
  • dehydration
1 - 2 years:
  • borderline personality disorder
  • depression
  • short-term memory loss
  • colitis collagenous
  • insomnia
  • ocd
2 - 5 years:
  • gastrointestinal haemorrhage
  • constipation
  • blood amylase increased
  • haemolysis
  • hepatic failure
  • influenza
  • joint pain
  • renal failure acute
  • unresponsive to stimuli
  • abdominal distension
5 - 10 years:
  • gastric ulcer
  • gastroduodenitis
  • hives
  • intestinal stenosis
  • bloody sputum
  • crohn's disease
10+ years:
  • bad breath
  • bleeding gums
  • dry mouth
  • hives
  • mouth sores
  • pain - tooth or teeth
  • sensitivity of teeth
  • tooth decay
not specified:
  • diarrhoea
  • crohn's disease
  • nausea
  • fatigue
  • anaemia
  • abdominal pain
  • pain
  • vomiting
  • colitis ulcerative
  • anxiety

Most common drug interactions by gender *:

female:
  • diarrhoea
  • crohn's disease
  • nausea
  • anaemia
  • fatigue
  • pain
  • colitis ulcerative
  • abdominal pain
  • arthralgia
  • anxiety
male:
  • diarrhoea
  • abdominal pain
  • crohn's disease
  • vomiting
  • asthenia
  • nausea
  • weight decreased
  • fatigue
  • abdominal pain upper
  • pain

Most common drug interactions by age *:

0-1:
  • muscular weakness
  • tremor
  • abdominal pain
  • abscess
  • anaemia
  • cerebrovascular accident
  • clostridium difficile colitis
  • colitis ulcerative
  • constipation
  • dehydration
2-9:
  • foetal exposure during pregnancy
  • premature baby
10-19:
  • crohn's disease
  • hepatosplenic t-cell lymphoma
  • renal failure
  • sinus disorder
  • clostridial infection
  • collapse of lung
  • cellulitis
  • colitis ulcerative
  • abdominal pain
  • nausea
20-29:
  • diarrhoea
  • crohn's disease
  • fatigue
  • abdominal pain
  • colitis ulcerative
  • drug ineffective
  • injury
  • emotional distress
  • pain
  • headache
30-39:
  • abdominal pain
  • vomiting
  • diarrhoea
  • nausea
  • headache
  • abdominal pain upper
  • depression
  • pyrexia
  • anxiety
  • gastritis
40-49:
  • crohn's disease
  • pain
  • diarrhoea
  • deep vein thrombosis
  • chronic obstructive pulmonary disease
  • hiatus hernia
  • anxiety
  • colitis ulcerative
  • anaemia
  • cardiac failure congestive
50-59:
  • diarrhoea
  • pain
  • anaemia
  • fatigue
  • colitis ulcerative
  • oedema peripheral
  • gastrooesophageal reflux disease
  • renal failure
  • abdominal pain
  • asthma
60+:
  • nausea
  • diarrhoea
  • dyspnoea
  • hypotension
  • anaemia
  • weight decreased
  • fatigue
  • asthenia
  • fall
  • dehydration

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Pantoprazole sodium and Mesalamine?

Can you answer these questions?

More questions for: Pantoprazole sodium, Mesalamine

You may be interested in these reviews

More reviews for: Pantoprazole sodium, Mesalamine

On eHealthMe, Pantoprazole sodium (pantoprazole sodium) is often used to treat gastrooesophageal reflux disease. Mesalamine (mesalamine) is often used to treat crohn's disease. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.